ARID5B

Overview

ARID5B (AT-rich interaction domain 5B) is a member of the ARID family of chromatin-remodeling proteins closely related to ARID1A. It was identified as a newly recurrently mutated SWI/SNF/ARID-family gene in endometrial carcinoma by the TCGA integrated genomic characterization study, with enrichment in MSI tumors.

Alterations observed in the corpus

  • Newly identified as a recurrently mutated SWI/SNF/ARID-family gene in endometrial carcinoma (ucec_tcga_pub); mutated in 23.1% of MSI tumors vs. 5.6% of MSS endometrioid vs. 0% of serous-like subtype. PMID:23636398
  • Mutation observed in ACC WES cohort (n=60); implicated in histone modification complex function PMID:23685749
  • Somatic mutation in chromatin-remodeling gene cluster; collectively mutated in 12/24 ACC cases in exome-sequencing discovery cohort PMID:23778141
  • Chromatin remodeler truncated or hit at COSMIC sites in cutaneous squamous cell carcinoma; part of SWI/SNF complex alterations observed in 48% of 29-tumor cSCC cohort PMID:25589618
  • ARID5B, as part of the SWI/SNF complex, mutated in 36% ATC vs 6% PDTC (P = 1×10⁻⁴) in a 341-gene targeted sequencing cohort (n=117 advanced thyroid tumors); first report of SWI/SNF disruption in advanced thyroid cancer PMID:26878173
  • ARID5B identified as an additional context gene in disease-state enrichment analyses of prostate cancer progression (locoregional to mCRPC) alongside FOXA1 PMID:28825054
  • Mutations in ARID5B are associated with better survival in GCB DLBCL (1001-patient cohort); ARID5B is classified as a survival modifier in GCB subtype PMID:28985567

Cancer types (linked)

  • UCEC (uterine corpus endometrial carcinoma): enriched in the MSI subtype (23.1%), present at low frequency in MSS endometrioid (5.6%), and absent in serous-like tumors, mirroring the pattern of other SWI/SNF-family members. PMID:23636398

Co-occurrence and mutual exclusivity

  • Co-occurs with high MSI burden, consistent with the MSI (MC2) molecular subtype of endometrial carcinoma which harbors the highest mutation rates among non-POLE groups. PMID:23636398

Therapeutic relevance

  • As a SWI/SNF-family member, ARID5B loss-of-function may contribute to synthetic lethality strategies being explored for ARID1A-deficient tumors; no specific therapeutic data reported in this study. PMID:23636398

Open questions

  • Functional impact of ARID5B mutations on chromatin remodeling and endometrial tumor biology has not been directly validated; significance relative to ARID1A loss in the same tumors is unclear. PMID:23636398

Sources

This page was processed by crosslinker on 2026-05-09. - PMID:23685749

This page was processed by crosslinker on 2026-05-09. - PMID:23778141

This page was processed by crosslinker on 2026-05-09. - PMID:25589618

This page was processed by wiki-cli on 2026-05-14. - PMID:26878173

This page was processed by entity-page-writer on 2026-05-15. - PMID:28825054

This page was processed by entity-page-writer on 2026-05-15.